Panagora Asset Management Inc. Sells 2,532 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Panagora Asset Management Inc. trimmed its position in Charles River Laboratories International, Inc. (NYSE:CRL) by 36.7% in the first quarter, Holdings Channel reports. The fund owned 4,360 shares of the medical research company’s stock after selling 2,532 shares during the quarter. Panagora Asset Management Inc.’s holdings in Charles River Laboratories International were worth $880,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of CRL. Private Advisor Group LLC boosted its stake in shares of Charles River Laboratories International by 15.4% during the first quarter. Private Advisor Group LLC now owns 1,331 shares of the medical research company’s stock valued at $378,000 after purchasing an additional 178 shares in the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS increased its position in Charles River Laboratories International by 6.6% in the 1st quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 6,752 shares of the medical research company’s stock valued at $1,917,000 after acquiring an additional 418 shares during the period. Great West Life Assurance Co. Can raised its stake in shares of Charles River Laboratories International by 0.4% during the first quarter. Great West Life Assurance Co. Can now owns 25,049 shares of the medical research company’s stock valued at $7,465,000 after acquiring an additional 107 shares during the last quarter. Raymond James Trust N.A. lifted its holdings in shares of Charles River Laboratories International by 33.7% during the first quarter. Raymond James Trust N.A. now owns 1,525 shares of the medical research company’s stock worth $433,000 after purchasing an additional 384 shares during the period. Finally, Sei Investments Co. grew its stake in shares of Charles River Laboratories International by 1.2% in the first quarter. Sei Investments Co. now owns 94,869 shares of the medical research company’s stock worth $26,958,000 after purchasing an additional 1,104 shares during the last quarter. Institutional investors own 98.91% of the company’s stock.

Insider Buying and Selling

In related news, Director Richard F. Wallman acquired 1,000 shares of the firm’s stock in a transaction on Thursday, August 24th. The stock was purchased at an average cost of $198.79 per share, with a total value of $198,790.00. Following the acquisition, the director now owns 1,000 shares of the company’s stock, valued at approximately $198,790. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. In other news, VP William D. Barbo sold 5,763 shares of the business’s stock in a transaction that occurred on Thursday, August 10th. The stock was sold at an average price of $217.24, for a total value of $1,251,954.12. Following the transaction, the vice president now owns 3,592 shares in the company, valued at approximately $780,326.08. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Richard F. Wallman acquired 1,000 shares of Charles River Laboratories International stock in a transaction on Thursday, August 24th. The stock was acquired at an average price of $198.79 per share, with a total value of $198,790.00. Following the purchase, the director now directly owns 1,000 shares in the company, valued at $198,790. The disclosure for this purchase can be found here. Insiders have sold 7,934 shares of company stock worth $1,722,048 in the last quarter. Insiders own 1.30% of the company’s stock.

Charles River Laboratories International Price Performance

Shares of NYSE CRL opened at $204.42 on Friday. The firm has a market capitalization of $10.48 billion, a P/E ratio of 21.68, a P/E/G ratio of 1.83 and a beta of 1.33. The firm’s 50-day moving average price is $206.84 and its 200-day moving average price is $204.05. The company has a current ratio of 1.49, a quick ratio of 1.21 and a debt-to-equity ratio of 0.82. Charles River Laboratories International, Inc. has a 1-year low of $181.22 and a 1-year high of $262.00.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings results on Wednesday, August 9th. The medical research company reported $2.69 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.63 by $0.06. Charles River Laboratories International had a net margin of 11.58% and a return on equity of 18.99%. The business had revenue of $1.06 billion during the quarter, compared to the consensus estimate of $1.05 billion. During the same quarter last year, the firm posted $2.77 EPS. Charles River Laboratories International’s revenue was up 8.9% compared to the same quarter last year. Equities research analysts anticipate that Charles River Laboratories International, Inc. will post 10.48 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts have commented on CRL shares. TheStreet downgraded Charles River Laboratories International from a “b-” rating to a “c” rating in a report on Thursday, May 11th. JPMorgan Chase & Co. upped their target price on Charles River Laboratories International from $225.00 to $250.00 and gave the company an “overweight” rating in a report on Thursday, August 10th. Deutsche Bank Aktiengesellschaft lowered their price target on shares of Charles River Laboratories International from $260.00 to $250.00 in a report on Friday, May 12th. StockNews.com lowered shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a research note on Saturday, September 2nd. Finally, Credit Suisse Group lowered their target price on shares of Charles River Laboratories International from $260.00 to $255.00 in a research note on Friday, May 12th. Four investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $247.80.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc, a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).